Literature DB >> 10720146

Treatment of acute myelogenous leukemia in older adults.

J M Rowe1.   

Abstract

The overall strategy for the treatment of older adults is summarized in Table 8. Soon after the birth of effective chemotherapy for acute leukemia, the perspective for all patients was summarized as follows: 'With all humility it may be claimed that there are, at least, grounds for hope and encouragement in this recently acquired ability occasionally to halt for a while the formerly unrelenting malignant process known as acute leukemia'. In reviewing the overall survival data for older adults one may feel that we are at a similar juncture in assessing the outcome for this particular population. It is hoped that some of the potential advances may provide greater hope and improved results over the next decade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720146     DOI: 10.1038/sj.leu.2401539

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities.

Authors:  Irena Djunic; Nada Suvajdzic-Vukovic; Marijana Virijevic; Aleksandra Novkovic; Natasa Colovic; Ana Vidovic; Dragica Tomin
Journal:  Med Oncol       Date:  2012-12-29       Impact factor: 3.064

2.  Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.

Authors:  Wolfgang R Sperr; Susanne Herndlhofer; Karoline Gleixner; Michael Girschikofsky; Ansgar Weltermann; Sigrid Machherndl-Spandl; Thamer Sliwa; Rainer Poehnl; Veronika Buxhofer-Ausch; Karin Strecker; Gregor Hoermann; Paul Knoebl; Ulrich Jaeger; Klaus Geissler; Michael Kundi; Peter Valent
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

3.  Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia.

Authors:  Xavier Thomas
Journal:  World J Stem Cells       Date:  2009-12-31       Impact factor: 5.326

4.  Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia.

Authors:  Irena Djunic; Marijana Virijevic; Aleksandra Novkovic; Vladislava Djurasinovic; Natasa Colovic; Ana Vidovic; Nada Suvajdzic-Vukovic; Dragica Tomin
Journal:  Med Oncol       Date:  2011-02-18       Impact factor: 3.064

5.  Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.

Authors:  Dierk Thomas; Bettina C Hammerling; Kezhong Wu; Anna-Britt Wimmer; Eckhard K Ficker; Glenn E Kirsch; Mary C Kochan; Barbara A Wible; Eberhard P Scholz; Edgar Zitron; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

6.  Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.

Authors:  Bin-Tao Huang; Wei-Hong Zhao; Qing-Chun Zeng; Bing-Sheng Li; Rui-lin Chen
Journal:  Med Oncol       Date:  2014-04-18       Impact factor: 3.064

Review 7.  Treatment concepts for elderly patients with acute myeloid leukemia.

Authors:  Wolfgang R Sperr; Alexander W Hauswirth; Friedrich Wimazal; Paul Knöbl; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

Review 8.  Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

9.  Tipifarnib in the treatment of acute myeloid leukemia.

Authors:  Xavier Thomas; Mohamed Elhamri
Journal:  Biologics       Date:  2007-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.